Edition:
United States

ITUS Corp (ITUS.OQ)

ITUS.OQ on NASDAQ Stock Exchange Capital Market

2.81USD
2:41pm EST
Change (% chg)

$0.08 (+2.93%)
Prev Close
$2.73
Open
$2.73
Day's High
$2.83
Day's Low
$2.71
Volume
13,207
Avg. Vol
298,599
52-wk High
$6.10
52-wk Low
$0.60

Summary

Name Age Since Current Position

Amit Kumar

53 2017 Chairman of the Board, President, Chief Executive Officer

Michael Catelani

50 2017 Chief Financial Officer, Chief Operating Officer

Arnold Baskies

68 2016 Director

Dale Fox

50 2014 Independent Director

John Monanhan

70 2016 Independent Director

Lewis Titterton

73 2017 Independent Director

Dean Krouch

2016 IR Contact Officer

Biographies

Name Description

Amit Kumar

Dr. Amit Kumar, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of the Company. He served as Director since November 2012, Strategic Advisor since September 2012, Vice Chairman of the Board, Executive Chairman and Chief Executive officer of Anixa Diagnostics since June 15, 2015 of the company. Upon his appointment as Executive Chairman of Anixa, Dr. Kumar resigned from his position as the CEO of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010, Dr. Kumar was President and CEO of CombiMatrix Corporation, a NASDAQ listed biotechnology company and also served as director from September 2000 to June 2012. Dr. Kumar was Vice President of Life Sciences of Acacia Research Corporation, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007, and as a director of Aeolus Pharmaceuticals, Inc. since June 2004. Dr. Kumar holds an A.B. in Chemistry from Occidental College and Ph.D. from Caltech and completed his post-doctoral training at Harvard University. Dr. Kumar has experience in technology driven startups, both at the board and operating levels, in a broad variety of areas including finance, acquisitions, R&D, and marketing, and has served as a director and officer of another publicly traded company.

Michael Catelani

Mr. Michael J. Catelani is the Chief Financial Officer, Chief Operating Officer of the Company. Mr. Catelani is a seasoned executive with over 25 years of experience in finance, auditing, and operations. Previously, Mr. Catelani co-founded Tacere Therapeutics, Inc., a privately held biotechnology company, and served as its Chairman, President and Chief Financial Officer until its sale. Prior to Tacere, Mr. Catelani served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotechnology company. Prior to Benitec, Mr. Catelani served as Vice President and Chief Financial Officer at Axon Instruments, a U.S. corporation publicly traded on the Australian Stock Exchange that is a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Prior to Axom, Mr. Catelani served as the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mr. Catelani has also worked with several early stage start-up companies in a variety of industries, including biotechnology, retail, waste water recovery, and distributed power generation, in both advisory and management roles and has served as a contract Chief Financial Officer to a number of established businesses in the biotechnology field. Mr. Catelani began his professional career at Ernst & Young and is a CPA. He received his B.S. degree in business administration, with a concentration in accountancy, from Sacramento State University and earned his MBA from the University of California, Davis.

Arnold Baskies

Dr. Arnold Baskies is Director of the Company, Dr. Baskies, Vice Chairman of the National Board of Directors of the American Cancer Society, is a board certified general surgeon and fellowship trained surgical oncologist with special interests in breast cancer, thyroid cancer, and melanoma. Dr. Baskies has been a member of Virtua Surgical Specialists, a multi-specialty practice since 2011. In addition to his pioneering efforts to promote the latest surgical and nonsurgical techniques, including minimally invasive surgery (and advanced radioguided techniques) for diseases of the breast, thyroid, and parathyroid glands, he has cared for thousands of surgical patients in his 30-year career. Dr. Baskies received his Bachelor of Arts degree summa cum laude and was a member of Phi Beta Kappa at Boston University, graduated from the Boston University School of Medicine, completed his surgical residency at Boston Medical Center, and had fellowship training in surgical oncology at the National Cancer Institute.

Dale Fox

Mr. Dale Fox is the Independent Director of Itus Corp., since 2014. Mr. Fox is an entrepreneur and innovator who has launched many companies. He is currently the CEO of Tribogenics, a start-up company he co-founded in 2010 that develops portable, powerful X-ray devices based, in part, upon a technology conceived and licensed from the University of California, Los Angeles. Mr. Fox has raised numerous rounds of capital for many types of companies, including venture capital, strategic investments, and other financings. Mr. Fox has built executive and advisory teams. He received a Bachelor of Business Administration degree from Southern Methodist University’s Cox School of Business. Since 2009, Mr. Fox has taught at the Founders Institute where he teaches classes on start-ups and continues to mentor young entrepreneurs. Mr. Fox is an experienced startup entrepreneur and inventor who has successfully launched a number of companies. As a result, Mr. Fox has gained experience is a broad variety of other areas including finance, research and development and marketing.

John Monanhan

Dr. John Monanhan is Independent Director of the Company.

Lewis Titterton

Mr. Lewis H. Titterton, Jr., is the Independent Director of the Company. He served as a director of the Company from August 2010 through August 2016, as the Chairman of the Board of Directors from July 2012 through August 2016, and interim Chief Executive Officer from August 2012 until September 2012. Mr. Titterton is currently Chairman of the Board of NYMED, Inc., a diversified health services company. His background is in high technology with an emphasis on health care and he has been with NYMED, Inc. since 1989. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. Mr. Titterton also served as one of our Directors from July 1999 to January 2003. He holds a M.B.A. from the State University of New York at Albany, and a B.A. degree from Cornell University. Mr. Titterton has been involved with our Company as a director or investor for over twenty years. Mr. Titterton also has substantial experience with advising on the strategic development of technology companies and over forty years of experience in various aspects of the technology industry.

Dean Krouch

Basic Compensation

Name Fiscal Year Total

Amit Kumar

1,078,900

Michael Catelani

--

Arnold Baskies

--

Dale Fox

--

John Monanhan

--

Lewis Titterton

136,575

Dean Krouch

--
As Of  30 Oct 2016

Options Compensation